Determining Prognostic Immune Markers in Patients With Ovarian Cancer
ConditionEpithelial Ovarian Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorLeiden University Medical Center
About this trial
The IMPRoVE study is a prospective, non-interventional, explorative cohort study to determine prognostic immune markers in patients with epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (EOC).
Eligibility criteria
Qualifiers
Patients with (suspicion of) primary or recurrent EOC with an indication for surgery, chemotherapy and/or immunotherapy.
Age ≥18 years.
WHO performance status 0-2.
Accessible for treatment and follow-up.
Disqualifiers
Other active malignancy in past 5 years prior to entry into the study, except for treated non-melanoma skin cancer.
Any known severe infection like HIV, hepatitis A, B and C.
Receiving immune suppressive treatment.
Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent.
Trial design
Treatments tested in this trial
- No intervention
Treatment groups
300 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov